UBE2E3 sustains PRC1.1 function and leukemic stemness in acute myeloid leukemia

Inside the human body, a complex system of molecular switches controls how cells grow, divide, and decide what kind of tissue to become. In a healthy state, these switches ensure that blood cells mature properly and stop dividing when they should. However, in a dangerous form of blood cancer called acute myeloid leukemia, these controls break down. The cells refuse to mature and instead multiply uncontrollably, crowding out healthy blood cells. For decades, scientists have focused on the proteins that act as the primary brakes on this growth, but they have often overlooked a different class of molecules that help manage the very machinery of these brakes. Understanding how these supporting molecules work is crucial, because if the cancer cells rely on them to survive, finding a way to disrupt that support could offer a new path to treatment.

A team of researchers has now uncovered a vital piece of this puzzle. They discovered a specific protein, known as UBE2E3, which acts as a hidden guardian for the cancer cells in acute myeloid leukemia. This protein does not work alone; it partners with a large molecular machine called PRC1.1. You can think of PRC1.1 as a specialized team of workers that sits on the cell's genetic blueprint, deciding which genes to keep silent and which to allow to function. In leukemia, this team is hijacked to keep the cancer cells in a primitive, immature state, allowing them to keep dividing. The researchers found that UBE2E3 is essential for keeping the PRC1.1 team intact and functioning. Without UBE2E3, the team falls apart, and the cancer cells lose their ability to sustain themselves.

The investigation began by looking at patient samples. The researchers found that UBE2E3 was present in much higher amounts in the cancer cells of leukemia patients compared to healthy blood cells. This suggested that the cancer cells might be dependent on this protein to survive. To understand how it worked, the scientists used a technique that allowed them to see which other proteins UBE2E3 was physically touching inside the cell. They found that UBE2E3 was closely associated with the PRC1.1 complex, specifically with the core components that drive its activity. It was not just a random connection; the protein seemed to be holding the machinery together.

To test if this connection was real and important, the researchers removed UBE2E3 from leukemia cells in the laboratory. When they did this, the levels of key proteins within the PRC1.1 machine dropped significantly. The cells did not just stop growing; they began to change. The genetic programs that kept them in a primitive, cancerous state were turned off, and the cells started to show signs of maturing into normal blood cells. This change was not due to a lack of instructions in the genetic code, but rather because the physical building blocks of the PRC1.1 machine were disappearing. The researchers confirmed that UBE2E3 acts like a stabilizer, ensuring that these critical components remain at the right levels so the machine can function.

Crucially, the team discovered that this stabilizing role depends on the chemical activity of UBE2E3 itself. They created a version of the protein that looked the same but could not perform its chemical job. When they replaced the missing UBE2E3 with this inactive version, the PRC1.1 machine still fell apart, and the cancer cells did not recover. This proved that the protein's ability to perform its specific chemical task was necessary to keep the cancer machinery running. It was not enough for the protein to simply be present; it had to be active.

The final tests took the research from the laboratory dish to living models. When the researchers removed UBE2E3 from leukemia cells and transplanted them into mice, the cancer failed to take hold. The cells could not establish themselves in the bone marrow, and they lost the ability to start new rounds of cancer growth. This indicated that UBE2E3 is not just helpful for the cancer, but is actually required for the leukemia to survive and spread. Without it, the cancer cells lose their "stemness," a quality that allows them to act as the source of the disease.

These findings reveal a new layer of control in how leukemia cells maintain their identity. The study shows that a protein involved in tagging other molecules for recycling is actually essential for keeping a major gene-regulating machine intact. By linking the activity of UBE2E3 directly to the stability of the PRC1.1 complex, the researchers have identified a potential weak spot in the cancer's armor. If this protein can be targeted, it might be possible to dismantle the machinery that keeps the leukemia cells alive, forcing them to mature and die. This work moves the focus from the main actors in the cancer story to the essential support crew, suggesting that disrupting their connection could be a powerful new strategy for treating this difficult disease.